Annexon (ANNX) Could Be 95% Below Fair Value As Phase 3 Progress Reshapes Views

Annexon (ANNX) is in focus after reporting positive Phase 3 data for tanruprubart in Guillain-Barré syndrome, filing in Europe, planning a US FDA submission, and sharing progress on vonaprument in geographic atrophy.

See our latest analysis for Annexon.

Annexon’s recent clinical and regulatory updates arrive after a mixed price pattern, with the stock up 17.41% on a 1 month share price return and 23.67% year to date, but down 11.31% over 3 months. The 1 year total shareholder return of 150% contrasts with a 5 year total shareholder return that is still significantly lower, suggesting sentiment has improved more recently as investors reassess the company’s risk and pipeline potential.

If Annexon’s clinical progress has your attention, this can be a useful moment to look across the sector using our healthcare focused screeners, including 39 healthcare AI stocks

Bulls view Annexon’s Phase 3 win and regulatory filings as the beginning of a rerating, while bears highlight a loss-making, pre-revenue business and volatile returns. As you weigh the risk and reward, which side does the current valuation appear to favor?

Preferred Price to Book Multiple of 4.6x: Is it justified?

Annexon closed at $5.80, and on a P/B of 4.6x it trades at a richer level than many biotech peers that are also pre revenue and loss making.

P/B compares the company’s market value to its accounting equity, which can be a useful cross check for asset light biotechs that do not yet have meaningful revenue or profits. For Annexon, the current multiple sits alongside a reported net loss of $198.33m and revenue of $0. In that context, the market is effectively paying up for the clinical pipeline and the forecast transition toward profitability.

Against this backdrop, Annexon screens as expensive relative to both the broader US Biotechs industry P/B of 2.6x and the peer average of 4.1x. This indicates that investors are assigning a premium to the company’s future prospects rather than its current balance sheet, even as analysts’ price targets and DCF style fair value estimates indicate a very large implied difference compared with today’s share price.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book ratio of 4.6x (OVERVALUED)

However, Annexon still carries clear risks, including ongoing losses of $198.333m with no current revenue and the possibility of clinical or regulatory setbacks across its pipeline.

Find out about the key risks to this Annexon narrative.

Another View on Annexon: What the DCF Model Suggests

While Annexon looks expensive on a P/B of 4.6x, the SWS DCF model paints a very different picture. At a share price of $5.80 versus an estimated future cash flow value of $121.33, the stock is described as trading roughly 95.2% below that fair value estimate. Which signal do you trust more: the balance sheet multiple or the cash flow outlook?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Annexon for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing both opportunity and risk around Annexon, it makes sense to move quickly, review the underlying data for yourself, and decide where you stand on the stock. To weigh those mixed signals in one place, start with the 2 key rewards and 2 important warning signs.

Looking for more Annexon sized investment ideas?

Annexon might already be on your radar, but you do not want to stop at a single stock when there are other focused opportunities worth comparing.

Use the Simply Wall Street Screener to uncover fresh ideas that match your style and risk appetite, before the crowd shifts its attention.

• Target potential mispricings by scanning 47 high quality undervalued stocks that combine solid fundamentals with room for improvement in sentiment.
• Strengthen the income side of your portfolio by reviewing 8 dividend fortresses that emphasise higher yields with an eye on resilience.
• Reduce surprises by concentrating on 84 resilient stocks with low risk scores that score well on balance sheet strength and overall risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com